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The chemokine interleukin-8 (IL-8) has chemoattractant activity for neutrophils and is able to activate and
degranulate these cells. We investigated whether IL-8 may exert these effects in children with dengue virus infection.
Circulating levels of IL-8, neutrophilic elastase (a constituent of the azurophilic granula of neutrophils), and
lactoferrin, released from specific granula, were measured in 186 children with dengue virus infection, 33
healthy children as negative controls and 11 children with bacterial infections as positive controls. Levels of
IL-8 on admission were elevated in 71% of the dengue patients, while the elastase and lactoferrin levels were
increased in 68 and 17% of patients, respectively. These levels were significantly higher than in healthy children
(P < 0.05) for IL-8 and elastase but not for lactoferrin (by the Wilcoxon-Mann-Whitney [WMW] U test).
Similar levels of IL-8 were found in patients with bacterial infections. Levels of IL-8 and elastase in patients
with shock were significantly higher than in patients without shock (P 5 0.02; WMW), but those of lactoferrin
were not. IL-8 correlated with elastase and lactoferrin (r 5 0.19 and P 5 0.009 versus r 5 0.24 and P 5 0.001,
respectively; two-tailed Spearman rank correlation). Thus, IL-8 levels are increased in most patients with
dengue virus infection and correlate with degranulation of neutrophils as well as with some clinical and
hemodynamic variables. These findings suggest a role for IL-8 in the pathogenesis of dengue virus infection.
Dengue fever (DF) is an acute infectious disease of viral
etiology characterized by biphasic fever, headache, pain in
various parts of the body, prostration, rash, lymphadenopathy,
and leukopenia. Severe cases designated as dengue hemor-
rhagic fever (DHF) are characterized by abnormalities of he-
mostasis and by increased vascular permeability. In some pa-
tients the dengue shock syndrome (DSS) develops, which has a
high mortality rate (17, 18).
The pathogenesis of the shock syndrome in dengue virus
infection is still under debate. The primary targets of dengue
virus infection are monocytes (19). On histologic examination,
swelling and hyaline necrosis of Kupffer cells are commonly
seen (5). Also, by using electron microscopy, crystalline arrays
of spherical dengue virus-like particles have been observed in
the cytoplasma of monocytes of children with DHF-DSS (6).
With immunofluorescence techniques, dengue virus antigen
has been found to be localized in the cytoplasm of mononu-
clear cells (7). The dengue virus-infected monocytes presum-
ably become activated to produce various factors (inflamma-
tory mediators), which result in rash, shock, and hemorrhages
(19). Among the mediators involved are neutrophils, plasma
cascade systems (such as the complement system), and cyto-
kines (4, 19). In particular, the latter are considered to play an
important role in the pathogenesis of dengue virus infection.
Dengue virus-infected fibroblasts produce interleukin-6 (IL-6)
and granulocyte-macrophage colony-stimulating factor (30). In
addition, elevated plasma levels of cytokines such as tumor
necrosis factor (TNF), IL-6, IL-8, and alpha interferon have
been found in patients with severe dengue virus infection (3,
23, 29, 37, 49, 53).
IL-8, a cytokine with potential proinflammatory effects (1,
46, 51), has chemoattractant activity (9, 10, 42, 45, 54) and is
able to activate and degranulate neutrophils (11, 36, 42). In
vitro, IL-8 is produced by a variety of cells, including mono-
cytes, macrophages, and endothelial cells (1, 35). In vivo, IL-8
is an important regulator of neutrophil activation and migra-
tion (22).
Neutrophils are equipped to destroy ingested microorgan-
isms by the generation of a variety of toxic products such as
oxygen radicals and by the release of proteinases such as elas-
tase and cathepsin G from primary or azurophilic granules and
proteins such as lactoferrin from secondary or specific granules
(2, 12–14, 26). In addition, elevated plasma levels of elastase
and lactoferrin reflect degranulation of neutrophils (34). Neu-
trophil elastase is considered to be important for neutrophil-
mediated endothelial injury (44, 47, 50). Neutrophil elastase
may also facilitate activation of complement, coagulation, and
the fibrinolytic system by inactivating the major inhibitors of
these systems (25, 41).
In this study we investigated the possible role of activation of
neutrophils as assessed by circulating elastase and lactoferrin
levels and its relation to IL-8 in the pathogenesis of dengue
virus infection.
MATERIALS AND METHODS
Patients. The children who were included in this study were admitted to the
Pediatric Department of Dr. Sardjito Hospital, Yogyakarta, Indonesia, with a
clinical diagnosis of fever lasting 2 to 7 days. The diagnosis of DF and DHF was
assigned to children according to World Health Organization (WHO) criteria
(52), and the severity of DHF was graded as follows: grade I, fever accompanied
by nonspecific constitutional symptoms with a positive tourniquet test as the only
hemorrhagic manifestation; grade II, same as grade I, but with spontaneous
hemorrhagic manifestations; grade III, circulatory failure manifested by a rapid,
weak pulse with narrowing of the pulse pressure (,20 mm Hg) or hypotension;
grade IV, profound shock with undetectable blood pressure and pulse (52). The
definitive diagnosis of dengue virus infection was made when patients had ele-
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vated levels of immunoglobulin M (IgM) antibodies with or without detectable
IgG antibodies against a dengue virus (52).
In all patients, clinical signs were monitored during their stay in the hospital.
All patients were treated with supportive therapy, including the infusion with
cristalloids, as well as plasma or fresh whole blood when necessary as a standard
therapy. The protocol was approved by the Medical Ethics Committee of the
Faculty of Medicine Gadjah Mada University, Dr. Sardjito Hospital. Informed
consent was obtained from the parents of each patient included in the study.
Blood sampling. Blood samples were obtained from patients via the vena
mediana cubiti. Blood was collected on admission and in some patients on
subsequent days during their hospital stay in tubes containing SBTI (100 pg/ml),
benzamidine (10 mmol), and EDTA (10 mmol/liter [final concentration]) to
prevent in vitro activation of complement and the contact system of coagulation.
The tubes were centrifuged for 10 min at 1,300 3 g, and plasma was stored at
270°C until tests were performed.
Blood samples from 33 apparently healthy children in the outpatients’ depart-
ment and from 11 children with a diagnosis of a bacterial infection such as sepsis,
bacterial meningitis, and typhoid fever, who served as negative and positive
controls, respectively, and who were treated according to the same procedure. In
all blood samples the total leukocyte count, platelet count, total protein concen-
tration, and IL-8, elastase, and lactoferrin levels were measured.
Laboratory investigations. Antibodies against dengue virus were measured by
enzyme-linked immunosorbent assay (ELISA). For the detection of dengue
virus-specific IgM antibodies, an ELISA was used (48). Dengue virus-specific
IgG antibodies were measured by using the indirect ELISA system (48).
IL-8 was measured with an ELISA obtained from the Central Laboratory of
the Netherlands Red Cross Blood Transfusion Service, Amsterdam, according to
the manufacturer’s instructions (16). Elastase (complexed to a1-antitrypsin) and
lactoferrin were determined with radioimmunoassays as described earlier (34).
Leukocyte and platelet numbers were assessed according to standard techniques.
Plasma protein was measured with a microhematocrit method. Heparin-blood
was centrifuged for 10 min at 10,000 to 12,000 rpm (31). The supernatant was
analyzed for protein content with a refractometer (Atago SPRN; Atago Co.,
Ltd.).
Analysis of data. Differences in age between groups were analyzed by the
analysis-of-variance test, and the gender distribution was analyzed by the chi-
square test. Differences between patient subgroups or between patient groups
and controls and differences between patients with shock or without shock, as
well as between the levels of IL-8, elastase, and lactoferrin in patients with or
without abnormal clinical parameters were evaluated with the Wilcoxon-Mann-
Whitney U mean rank test. Correlations between variables were evaluated with
the Spearman correlation test. Statistical significance was accepted at a two-
tailed P of ,0.05. All calculations were done with SPSS 6.0 software for Windows
95.
RESULTS
Patients. During September 1995 to May 1996, 235 children
were admitted to the hospital with fevers lasting 2 to 7 days,
suggesting a dengue virus infection, and they were included in
the study. In 186 patients the diagnosis of dengue virus infec-
tion could be serologically confirmed (IgM with or without IgG
antibodies). A total of 71 patients fulfilled the WHO criteria
for DHF: 22 cases for DHF1 (11.8%), 20 cases for DHF2
(10.8%), 18 cases for DHF3 (9.7%), and 11 cases for DHF4
(5.9%). The other patients (n 5 115) with positive serology
were considered to suffer from DF (61.8%). The mean ages (in
years) of patients were as follows: with DF, 8.15 6 3.15; with
DHF1, 9.73 6 3.15; with DHF2, 8.50 6 3.28; with DHF3,
8.39 6 3.58; and with DHF4, 7.40 6 2.32. The distribution of
gender was as follows: DF, 51.8% male, 48.2% female; DHF1,
68.2% male, 31.8% female; DHF2, 40% male, 60% female;
DHF3, 33.3% male, 66.7% female; and DHF4, 54.5% male,
45.5% female. There was no statistically significant difference
in age and gender distribution between the groups (analysis of
variance, P 5 0.24; chi-square, P 5 0.2 [respectively]).
IL-8 levels. Levels of IL-8 in plasma samples obtained from
33 healthy children ranged from ,20 to 45 pg/ml (median, ,20
pg/ml) (Table 1; Fig. 1). Elevated levels, i.e., $20 pg/ml, were
found in 30.3% of these endemic negative controls.
In the plasma samples obtained on admission from the den-
gue virus-infected patients, IL-8 levels were elevated in 70.5%
(Table 1), with a range of ,20 to 482 pg/ml and a median of 30
pg/ml. In three patients not enough plasma was available for
IL-8 measurement: two in the DF group and one in the DHF1
group. The highest proportion of elevated IL-8 levels was
found in the DHF4 group (90.9%), with a range of ,20 to 288
pg/ml and a median of 80 pg/ml, followed by the DHF1 (81%),
DHF2 (80%), DF (66.4%), and DHF3 (61.1%; see Table 1)
groups. In the group with bacterial infection (positive control),
the median plasma level of IL-8 was 51 pg/ml, with a range of
,20 to 839. Levels were elevated in most (90.9%) patients
(Table 1; Fig. 1).
Plasma levels of IL-8 in the dengue virus-infected patient
groups were significantly higher than those in the healthy child
FIG. 1. Levels of IL-8 in healthy children, in the dengue virus infection
group, and in bacterial infections. DHFI to -IV, DHF1 to -4; C2, negative
control; C1, positive control. The line indicates the median. In dengue patients
IL-8 was measured in plasma obtained upon admission; in the bacterial infection
group it was measured within 48 h of diagnosis.
TABLE 1. Plasma levels of IL-8, elastase, and lactoferrin on admission in the various groups of patientsa
Group
IL-8 Elastase Lactoferrin
n Median (range)(pg/ml) % Elevated n
Median (range)
(ng/ml) % Elevated n
Median (range)
(ng/ml) % Elevated
DF 113 28* (,20–482) 66.4 114 128° (36–5,080) 59.6 114 160† (25–3,000) 16.7
DHF1 21 34* (,20–137) 81 22 146.5° (64–1,564) 72.7 22 187.5† (49–895) 27.3
DHF2 20 44* (,20–366) 80 20 129.5° (43–806) 85 20 127.5† (29–521) 10
DHF3 18 30.5* (,20–268) 61.1 18 173° (47–908) 83.3 18 174.5† (49–440) 5.6
DHF4 11 80* (,20–288) 90.9 11 270° (80–920) 90.9 11 222† (56–1,132) 36.4
Dengue virus infection 183 30* (,20–482) 70.5 185 137° (36–5,080) 68.1 185 163† (25–3,000) 17.3
Negative control 33 ,20 (,20–45) 30.3 33 89 (45–1,961) 39.4 33 144 (35–785) 12.1
Positive control 11 51 (,20–839) 90.9 11 355 (73–1,330) 81.8 11 1,048 (86–2,208) 54.5
a Significance values: *, P , 0.05 compared to negative control and P . 0.05 compared to positive control except in groups DF and DHF1; °, P , 0.05 compared
to negative control and P . 0.05 compared to positive control except in the total dengue group, DF, and DHF2; †, P . 0.05 compared to negative control and P ,
0.05 compared to positive control except in group DHF4.
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group (Table 1), whereas levels were not different between the
dengue virus infection patient groups and the bacterial infec-
tion patient group, except for the levels in patients with DHF1
and DF (Table 1). In 82 patients blood samples for IL-8 mea-
surement were available on the day after admission (day 2),
and in 34 patients they were available on day 3. In the dengue
patients in whom serial measurements were available, the high-
est levels of IL-8 occurred in almost all patients on admission
and typically decreased in the following days.
Elastase and lactoferrin levels. In all patients except one
(in the DF group) elastase and lactoferrin were measured in
plasma obtained upon admission. Plasma levels of elastase
were elevated in 68.1% and those of lactoferrin were elevated
in 17.3% of patients with dengue virus infection (Table 1;
Fig. 2 and 3). Elastase levels in the patients with dengue virus
infection were significantly higher than in healthy children,
whereas elastase levels were similar to those in patients with
bacterial infections (Table 1; Fig. 2). Plasma levels of lactofer-
rin were comparable to those in the healthy children (Table 1;
Fig. 3).
Relationship of elevated plasma levels of IL-8 and the pres-
ence of shock. Of the 186 patients with dengue virus infection,
29 fulfilled the WHO criteria for shock (DHF3 plus DHF4).
Plasma levels of IL-8 and elastase on admission were signifi-
cantly higher in patients who developed shock during their
hospital stay than those in patients without shock (Table 2),
whereas plasma levels of lactoferrin were comparable be-
tween patients with or without shock (Table 2). Thus, elevated
plasma levels of IL-8 and elastase were significantly associated
with the development of shock, although there was consider-
able overlap of these variables between patients with and those
without shock.
Relationship of IL-8 to neutrophil elastase and lactoferrin.
Plasma levels of IL-8 correlated significantly, although weakly,
with those of elastase (r 5 0.19, P 5 0.009), as well as with
those of lactoferrin (r 5 0.24, P 5 0.001).
Relationship of plasma levels of IL-8 elastase, lactoferrin,
and clinical and laboratory variables. We tried to correlate
admission levels of IL-8, elastase, and lactoferrin with highest
or lowest values of some continuous laboratory and clinical
variables measured during hospital stay (Table 3). The levels of
these mediators were also compared between patients who
developed clinical complications such as ascites, pleural effu-
sion, or extremely cold extremities, as well as abnormal clotting
parameters during their hospital stay and patients who did not
show these abnormalities (Table 4).
A negative weak correlation was found between plasma lev-
els of IL-8 with platelet count, and a positive weak correlation
was found with heart rate (Table 3). Plasma levels of IL-8 in
patients with ascites, pleural effusion, cold extremities, and
decreased fibrinogen levels were higher than those in whom
these abnormalities were not present (Table 4). Also, IL-8
levels were higher in patients with a prolonged activated partial
thromboplastin time and clotting time than in patients in
whom these variables were normal. We found a negative cor-
relation between plasma levels of elastase with plasma protein
levels and with platelet count and a weak positive correlation
with leukocyte count as well (Table 3). Patients with ascites,
pleural effusion, cold extremities, and decreased fibrinogen
levels had higher plasma levels of elastase than patients with-
out these abnormalities (Table 4). Body temperature and leu-
kocyte count were significantly correlated with plasma levels of
lactoferrin (Table 3), but no differences were found in lacto-
ferrin levels between patients with and those without clinical
FIG. 2. Levels of elastase in healthy children, in the dengue virus infection
groups, and in those with bacterial infections. DHF I to IV, DHF1 to -4; C2,
negative control; C1, positive control. The line indicates the median. In dengue
patients IL-8 was measured in plasma obtained on admission; in the bacterial
infection group it was measured within 48 h of diagnosis.
FIG. 3. Levels of lactoferrin in healthy children, in dengue virus infection
groups, and in those with bacterial infections. DHFI to IV, DHF1 to -4; C2,
negative control; C1, positive control. The line indicates the median. In dengue
patients IL-8 was measured in plasma obtained on admission; in the bacterial
infection group it was measured within 48 h of diagnosis.
TABLE 2. Plasma levels of IL-8, elastase, and lactoferrin on
admission in patients with shock versus normotensive
patients with dengue virus infectiona
Group
IL-8 Elastase Lactoferrin
n
Median
(range)
(pg/ml)
n
Median
(range)
(ng/ml)
n
Median
(range)
(ng/ml)
Shock 29 54 (,20–288) 29 181 (47–920) 29 180 (49–1,132)
Normotensive 154 29 (,20–482) 156 131 (36–5,080) 156 160 (25–3,000)
a P 5 0.03, 0.009, and 0.23 for IL-8, elastase, and lactoferrin, respectively.
TABLE 3. Relation of admission IL-8, elastase, and lactoferrin
levels to laboratory and hemodynamic parameters
Parametersa
IL-8 Elastase Lactoferrin
n r P n r P n r P
Hematocrit (max) 180 0.02 0.7 182 0.13 0.07 182 20.02 0.7
Leukocyte count (max) 181 0.02 0.7 183 0.15 0.04 183 0.15 0.04
Platelet count (min) 181 20.15 0.04 183 20.27 ,0.01 183 20.04 0.6
Plasma protein (min) 177 0.03 0.7 179 20.42 ,0.01 179 20.09 0.2
Heart rate (max) 178 0.15 0.05 180 0.14 0.06 180 0.12 0.1
Temp (max) 177 0.12 0.1 179 0.14 0.06 179 0.17 0.02
a max, maximal value during hospital stay; min, minimal value during hospital
stay.
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abnormalities and abnormal coagulation variables (except par-
tial thromboplastin time), as shown in Table 4.
Relationship of IL-8, elastase, and lactoferrin and sequen-
tial infection. A total of 53 patients had suspected primary
dengue virus infection (IgM positive, IgG negative), whereas
131 patients had suspected secondary infection (IgM positive,
IgG positive). Two patients could not be classified because of
missing IgG results in the presence of a positive IgM result.
Levels of IL-8 and of lactoferrin were comparable in patients
with primary or secondary infection. On the other hand,
plasma levels of elastase were significantly higher in patients
with secondary infections than in patients with primary infec-
tions (P 5 0.01).
DISCUSSION
In this study we found elevated plasma levels of the chemo-
kine IL-8 and the neutrophil degranulation products elastase
and lactoferrin in patients with dengue virus infection. In ca.
70% of these patients, IL-8 and elastase levels were increased,
whereas only 17% had increased plasma concentrations of
lactoferrin. Levels of these mediators significantly correlated
with each other. Moreover, levels of IL-8 and elastase mea-
sured on admission were higher in patients who developed
shock and in patients with ascites or pleural effusion, which was
not the case for lactoferrin.
In several diseases, such as bacterial meningitis, sepsis, or
typhoid fever, the plasma levels of IL-8 are markedly increased
in the majority of patients (16, 27). In agreement with those
findings, we found increased levels in 90.9% of patients with a
bacterial infection tested as positive controls. Levels in these
patients were similar to those in patients with dengue virus
infection. Occasionally, IL-8 is increased in patients with sepsis
by more than 1,000-fold relative to values in healthy controls
(16). In the present study, circulating IL-8 was only moderately
elevated in about 70% of the patients, though patients with a
more severe form of DF more often had elevated IL-8 levels.
In sepsis IL-8 levels are usually the highest on admission (16).
Since patients with dengue virus infection usually are not ad-
mitted to the hospital before the third or fourth day after onset
of fever or even later, we cannot exclude the possibility that we
missed high levels occurring in the early stages of the disease.
The plasma levels of IL-8 in the patients with shock were
higher than in normotensive patients (Table 2), although the
difference was of borderline statistical significance. In addition,
we found a correlation between IL-8 levels and the clinical
signs of ascites, pleural effusion, and cold extremities. Thus, it
is conceivable that high levels of IL-8 in patients with dengue
virus infection may correlate with plasma leakage, which is a
mechanism contributing to the development of shock in severe
DHF. Our data are somewhat at variance with data from a
recent study of DHF involving 188 children with shock on
admission and 71 children who developed it later (3). This
study showed that in shock patients who survived there was no
increase of plasma levels of IL-8 whatsoever, but in patients
with fatal shock (n 5 6) the levels of IL-8 were markedly
increased (median, 200 pg/ml; range, 20 to 550 pg/ml) (3). Only
one of our patients died, and the difference between our results
and those described in the cited report (3) could result from
different assays and the limited number of shock patients in
our study. On the other hand, another recent study with 73
DHF patients showed an association of elevated IL-8 levels
with severity of illness and fatal outcome, a finding similar to
our results (37). Among patients with DHF1 10% had elevated
IL-8 levels, a percentage progressively increasing (together
TABLE 4. Relationships between levels of IL-8, elastase, and lactoferrin on admission with clinical and coagulation complications
Parametera
IL-8 Elastase Lactoferrin
n Median (range)(pg/ml) P n
Median (range)
(ng/ml) P n
Median (range)
(ng/ml) P
Ascites
Positive 40 54 (,20–366) 40 173 (53–1,564) 40 170 (39–1,132)
Negative 129 28 (,20–412) ,0.0001 131 127 (36–5,080) 0.003 131 163 (25–1,568) 0.9
Pleural effusion
Positive 27 54 (,20–366) 27 173 (47–920) 27 169 (29–715)
Negative 142 28.5 (,20–412) 0.01 144 126 (36–5,080) 0.02 144 161 (25–1,568) 0.7
Cold extremities
Positive 19 55 (,20–268) 19 252 (85–5,080) 19 195 (49–1,568)
Negative 159 29 (,20–482) 0.04 161 131 (36–2,248) 0.002 161 159 (25–3,000) 0.07
Fibrinogen
Decreased 17 92 (,20–366) 17 186 (53–806) 17 236 (56–895)
Normal 9 ,20 (,20–52) 0.001 9 95 (45–354) 0.04 9 190 (49–499) 0.5
APTT
Prolonged 12 ,20 (,20–152) 12 174.5 (45–908) 12 180 (49–444)
Normal 107 32 (,20–412) 0.0009 107 138 (43–5,080) 0.6 107 169 (25–1,568) 0.6
PTT
Prolonged 47 29 (,20–412) 47 125 (45–1,564) 47 125 (45–1,564)
Normal 67 36 (,20–366) 0.1 67 155 (43–5,080) 0.2 67 155 (43–5,080) 0.01
Clotting time
Prolonged 39 39 (,20–366) 39 149 (45–1,424) 39 156 (29–586)
Normal 68 27 (,20–412) 0.02 70 133 (43–2,248) 0.2 70 169 (25–1,180) 0.5
a APTT, activated partial thromboplastin time; PTT, partial thromboplastin time.
VOL. 68, 2000 IL-8 IN DENGUE VIRUS INFECTION 705
with mean values for IL-8) with the severity of illness up to
61% in DHF4 (37). All six nonsurviving patients had IL-8
plasma levels higher than 200 pg/ml.
Our study also provides evidence for neutrophil activation in
dengue virus infection as neutrophil degranulation products
(e.g., elastase and lactoferrin) in the circulation were in-
creased. The statistical-significance correlation between IL-8
and these degranulation products suggests that IL-8 is involved
in neutrophil activation in dengue virus infection, although
other agonists likely are involved as well. A significantly higher
level of elastase in patients with shock than in normotensive
patients suggests that this degranulation product may be in-
volved in the pathogenesis of shock. This is supported by the
fact that there was a correlation between elastase and some
clinical parameters (Table 4). Elastase as a neutrophil degran-
ulation product may facilitate activation of the complement,
thereby contributing to vasodilatation and increased capillary
permeability in dengue virus infection. Remarkably, the high
levels of IL-8 and elastase were not associated with high levels
of lactoferrin, indicating predominant release of azurophilic
granules.
In vitro studies have indicated that many cell types, including
monocytes, macrophages, and endothelial cells, can produce
IL-8 in response to stimulation with endotoxin, IL-1 or TNF-a
(1, 35). The latter agents also have been shown to induce IL-8
release in vivo. In dengue virus infection, monocytes are the
predominant primary cells to be infected (19). In addition,
pathological studies have shown the swelling of endothelial
cells of small vessels in dengue virus infection (32, 38, 40).
Thus, mononuclear cells, and possibly also endothelial cells,
stimulated during dengue virus infection may well be respon-
sible for the IL-8 release.
IL-8 is a chemoattractant, induces neutrophil degranulation,
promotes adherence of neutrophils to endothelium by increas-
ing integrin expression on neutrophils, and regulates trans-
endothelial migration of these cells (8, 24). High local con-
centrations of IL-8 induce neutrophil infiltration, edema
formation due to neutrophil mediated endothelial damage,
and subsequent plasma leakage (21). These proinflammatory
effects of IL-8, and the fact that levels of IL-8 were correlated
with the presence of ascites and pleural effusion, suggest a role
for IL-8 in the pathogenesis of increased microvascular per-
meability which may explain the association of IL-8 levels with
the development of shock (Table 3).
Results from previous studies have suggested that individu-
als who have a secondary infection are at significant risk for
developing DHF or Dengue shock syndrome (DSS) (20, 28,
39). However, cases of DHF or DSS have been documented in
patients experiencing dengue virus infections for the first time
(15, 33, 43). In this study only 5.8% of the patients with a
primary infection developed shock. This may be a reason why
in this study no significant difference in plasma levels of IL-8
between primary and secondary infections was found.
In conclusion, we show that circulating levels of IL-8 and of
neutrophilic degranulation products are increased in a number
of patients with dengue virus infection and correlate with sev-
eral important biochemical and clinical parameters. These data
suggest a role for IL-8 and neutrophils as inflammatory medi-
ators in the pathogenesis of dengue virus infection.
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